PNOC Protein
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PNOC Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Prepronociceptin</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>[PNOC](/genes/pnoc)</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>Nociceptin, Orphanin FQ, N/OFQ</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q13519](https://www.uniprot.org/uniprot/Q13519)</td>
</tr>
<tr>
<td class="label">Precursor Length</td>
<td>176 amino acids</td>
</tr>
<tr>
<td class="label">Mature Peptide</td>
<td>17 amino acids (nociceptin)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~20 kDa (prepro), ~2 kDa (mature)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>8p21</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Secreted; enriched in amygdala, hippocampus, hypothalamus, periaqueductal gray</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">NOP antagonists</td>
<td>Block nociceptin-mediated hippocampal LTP inhibition</td>
</tr>
<tr>
<td class="label">NOP agonists</td>
<td>Anxiolytic, anti-stress, HPA axis modulation</td>
</tr>
<tr>
<td class="label">Bifunctional NOP/μ ligands</td>
<td>Combined pain and mood modulation</td>
</tr>
<tr>
<td class="label">Nocistatin analogs</td>
<td>Functional nociceptin antagonism</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/obesity" style="color:#ef9a9a">Obesity</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
PNOC (Prepronociceptin) is the precursor protein for nociceptin/orphanin FQ (N/OFQ), a 17-amino-acid neuropeptide that acts as the endogenous ligand of the nociceptin opioid peptide (NOP) receptor (also called ORL1 or OPRL1). Encoded by the [PNOC](/genes/pnoc) gene on chromosome 8p21, prepronociceptin is processed through proteolytic cleavage to yield mature nociceptin and additional bioactive peptides including nocistatin and NocII[@meunier1995][@reinscheid1995]. Unlike classical opioid peptides, nociceptin does not bind μ, δ, or κ opioid receptors, instead acting exclusively through the NOP receptor to modulate pain processing, anxiety, reward circuitry, learning, and neuroinflammation[@lambert2008]. Dysregulation of the N/OFQ-NOP system has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and stress-related neuropsychiatric disorders.
Structure
Precursor Processing
Prepronociceptin is synthesized as a 176-amino-acid precursor containing a signal peptide, the nociceptin sequence (FGGFTGARKSARKLANQ), and additional peptide sequences flanked by dibasic cleavage sites. Prohormone convertases (PC1/PC2) cleave the precursor at paired basic residues to release three bioactive products[@meunier1995]:
Nociceptin/Orphanin FQ (N/OFQ): 17 residues, the primary NOP receptor agonist
Nocistatin: A peptide that functionally antagonizes some nociceptin effects
NocII (NCII): A C-terminal peptide with distinct bioactivityNociceptin Peptide Structure
Mature nociceptin (FGGFTGARKSARKLANQ) shares structural homology with dynorphin A at the N-terminus (Phe-Gly-Gly-Phe), which is critical for NOP receptor binding. However, the charged residues in positions 8-13 (RKSARK) confer NOP selectivity and prevent binding to classical opioid receptors[@reinscheid1995]. The peptide adopts a partially helical conformation upon receptor engagement.
Normal Function
Pain Modulation
Nociceptin exerts complex, context-dependent effects on nociception. Supraspinal administration is pronociceptive (blocks stress-induced analgesia), while intrathecal administration produces antinociception[@lambert2008]. This bidirectional effect reflects differential NOP receptor signaling in descending pain inhibitory circuits versus spinal dorsal horn [neurons](/entities/neurons).
Anxiety and Stress Response
The N/OFQ-NOP system is a major regulator of the stress response. Nociceptin inhibits corticotropin-releasing factor (CRF) release from the hypothalamus, attenuating hypothalamic-pituitary-adrenal (HPA) axis activation. NOP receptor agonists produce anxiolytic effects in animal models, while NOP knockout mice show increased anxiety-like behavior[@witkin2014]. Nociceptin-containing neurons in the amygdala and bed nucleus of the stria terminalis (BNST) modulate fear conditioning and extinction.
Learning and Memory
NOP receptor activation in the [hippocampus](/brain-regions/hippocampus) impairs [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and spatial memory formation. Nociceptin inhibits glutamate release from Schaffer collateral terminals and suppresses CA1 pyramidal neuron excitability, providing a tonic inhibitory influence on hippocampal plasticity[@bhatt1999]. NOP receptor antagonists enhance memory performance in rodent models.
Reward and Motivation
Nociceptin opposes dopaminergic reward signaling by inhibiting dopamine release in the nucleus accumbens and ventral tegmental area. This anti-reward function has implications for addiction and motivational deficits in neurodegeneration[@lambert2008].
Role in Neurodegeneration
Alzheimer's Disease
The N/OFQ-NOP system is significantly altered in [Alzheimer's disease](/diseases/alzheimers-disease). Cerebrospinal fluid nociceptin levels are elevated in AD patients and correlate with cognitive decline[@severini2002]. In the hippocampus, NOP receptor expression changes may contribute to memory impairment through excessive inhibition of LTP. Preclinical studies show that NOP receptor antagonists (e.g., J-113397, UFP-101) improve memory in AD mouse models by disinhibiting hippocampal glutamatergic transmission[@bhatt1999][@rorickkehn2012].
Parkinson's Disease
Nociceptin levels are altered in the basal ganglia of [Parkinson's disease](/diseases/parkinsons-disease) patients, with increased N/OFQ immunoreactivity in the [substantia nigra](/brain-regions/substantia-nigra) and striatum. NOP receptor activation inhibits nigrostriatal dopamine release, potentially exacerbating parkinsonian motor deficits. Conversely, NOP antagonism has shown benefit in preclinical PD models by enhancing dopaminergic transmission[@marti2005].
Neuroinflammation
Nociceptin modulates [microglial](/cell-types/microglia) activation and neuroinflammatory responses. NOP receptors are expressed on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes), where nociceptin can both suppress and enhance inflammatory cytokine production depending on the activation state. In chronic neuroinflammation associated with neurodegeneration, the N/OFQ system may shift from a protective anti-inflammatory role to a maladaptive one[@witkin2014].
Stress-Neurodegeneration Interface
Through its regulation of the HPA axis and cortisol release, the N/OFQ system intersects with the [cortisol-tau pathway](/mechanisms/cortisol-tau-pathway). Chronic stress-induced HPA axis dysregulation, if not adequately buffered by nociceptin's CRF-inhibitory function, can drive [tau hyperphosphorylation](/mechanisms/tau-hyperphosphorylation) through [GSK-3β](/entities/gsk3-beta) activation[@witkin2014].
Therapeutic Targeting
See Also
- [Neuropeptide Signaling](/mechanisms/neuropeptide-signaling)
- [Cortisol-Tau Pathway](/mechanisms/cortisol-tau-pathway)
- [Hippocampus](/brain-regions/hippocampus)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [UniProt: Q13519](https://www.uniprot.org/uniprot/Q13519)
- [NCBI Gene: PNOC](https://www.ncbi.nlm.nih.gov/gene/5368)
- [GeneCards: PNOC](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PNOC)
References
[Meunier JC, Mollereau C, Toll L, et al, Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor (1995)](https://pubmed.ncbi.nlm.nih.gov/7477349/)
[Reinscheid RK, Nothacker HP, Bourson A, et al, Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor (1995)](https://pubmed.ncbi.nlm.nih.gov/7477348/)
[Lambert DG, The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential (2008)](https://pubmed.ncbi.nlm.nih.gov/18413830/)
[Witkin JM, Statnick MA, Rorick-Kehn LM, et al, The biology of nociceptin/orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence (2014)](https://pubmed.ncbi.nlm.nih.gov/25258171/)
[Bhatt DK, Bhakta M, Nociceptin/orphanin FQ selectively blocks the presynaptically mediated component of long-term potentiation in the hippocampus (1999)](https://pubmed.ncbi.nlm.nih.gov/10571234/)
[Severini C, Improta G, Falconieri-Erspamer G, et al, The tachykinin peptide family (2002)](https://pubmed.ncbi.nlm.nih.gov/12052034/)
[Rorick-Kehn LM, Ciccocioppo R, Witkin JM, et al, Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using NOP receptor antagonists (2012)](https://pubmed.ncbi.nlm.nih.gov/22289717/)
[Marti M, Mela F, Fantin M, et al, Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15857680/)